Geoff Hackett

TL;DR: Specific evaluation, treatment guidelines, and algorithms were developed for every sexual dysfunction in men, including erectile dysfunction; disorders of libido, orgasm, and ejaculation; Peyronie's disease; and priapism.

TL;DR: The Panel's recommendations build on those developed during the first and second Princeton Consensus Conferences, first emphasizing the use of exercise ability and stress testing to ensure that each man's cardiovascular health is consistent with the physical demands of sexual activity before prescribing treatment for ED, and second highlighting the link between ED and CVD, which may be asymptomatic and may benefit from cardiovascular risk reduction.

TL;DR: It is suggested that the prevalence of premature ejaculation is considerably lower than previously thought and that ongoing research will lead to a more complete understanding of the pathophysiology as well as new efficacious and safe treatments for this sexual dysfunction.

TL;DR: A meta-analysis on the effect of TS on male sexual function and its synergism with the use of phosphodiesterase type 5 inhibitor (PDE5i) found that TS could be associated with an improvement in PDE5i outcome, but these results were not confirmed in placebo-controlled studies.

TL;DR: A comprehensive evidence-based guideline has been developed that is highly relevant for primary and secondary care professionals enabling them to work within the unique requirements of the UK healthcare system.